Advanced kidney cancer (RCC) View all clinical trials KEYTRUDA+ axitinib helped patientslive longercompared to sunitinib A clinical trial compared patients with advanced renal cell carcinoma who received KEYTRUDA, an immunotherapy, in combination with axitinib, a tyrosine kinase inhibitor (TKI), to thos...
Study illustrates changes to gut microbiome with CBM588 in kidney cancer Hannah Clarke July 16th 2024 “These findings provide a plausible mechanism for the enhanced clinical outcome with CBM588 now seen across 2 small, randomized trials,” write the authors. ...
Belzutifan, XmAbA 808, XL092, VB10.NEO, Savolitinib, RC198, NKT2152, NGM707, MEDI5752, ADI-270, ALLO 316, KO 2806, TT-10, Fruquintinib, AB 2100,and others are under different phases of advan...
Although current treatments for kidney cancer are biological agents targeting this commonly dysregulated pathway, no biomarker has been identified to select patients. Consequentially, small molecule inhibitors of VEGF and PDGF receptors, anti-VEGF-A monoclonal antibodies and mTOR inhibitors are used ...
Kidney cancer: Papillary features predict survival in ncRCCDespite the availability of evidence from clinical trials on the optimal treatment of patients with metastatic, clear-cell renal-cell carcinoma (RCC), only limited data are available on the treatment of those with non-clear-cell renal-cell...
The kidney cancer condition center is a comprehensive resource for cancer news & oncologist insights on kidney cancer. Read more about cancer at CURE.
(TKIs) astargeted therapiesrevolutionizing the treatment of metastatickidney cancerand improving patient survival as both first-line and second-line therapies. Multipleclinical trialshave established improved treatment strategies to maximize patient response. Despite these advances issues still remain regarding ...
and surge in health care expenditure, the kidney cancer therapeutics and diagnostics market is anticipated to witness growth in the market over the forecast period. However, the high cost associated with the treatment and low success rate in clinical trials for cancer drugs may restrain market growt...
In the first clinical study (NCT04068831) combining poly-ADP ribose polymerase (PARP) inhibitors with immune checkpoint blockade, talazoparib (Talzenna) plus avelumab (Bavencio), in patients with advanced kidney cancer, clinical benefits were not seen in multiple genomically defined metastatic r...
Clinical trials with larger numbers of patients are needed to confirm the vaccine's effectiveness and explore its full potential. An ongoing multicenter international randomized study uses a similar neoantigen-targeting personalized cancervaccinewill be administered in combination with immunotherapy pembrolizumab...